

## Supplementary Materials: Uprolides N, O and P from the Panamanian Gorgonian Octocoral *Eunicea succinea*

Daniel Torres-Mendoza, Yisett González, José Félix Gómez-Reyes, Héctor M. Guzmán, José Luis López-Perez, William H. Gerwick, Patricia L. Fernandez and Marcelino Gutiérrez

**Figure S1.** Uprolide N, <sup>1</sup>H-NMR spectrum

**Figure S2.** Uprolide N, <sup>13</sup>C-NMR spectrum

**Figure S3.** Uprolide N, <sup>13</sup>C-NMR-DEPT 135 spectrum

**Figure S4.** Uprolide N, <sup>1</sup>H-<sup>1</sup>H-COSY spectrum

**Figure S5.** Uprolide N, HSQC spectrum

**Figure S6.** Uprolide N, HMBC spectrum

**Figure S7.** Uprolide N, 1D NOE irradiation on H-1

**Figure S8.** Uprolide N, 1D NOE irradiation on H-6

**Figure S9.** Uprolide N, 1D NOE irradiation on H-7

**Figure S10.** Uprolide N, 1D NOE irradiation on H-11

**Figure S11.** Uprolide N, 1D NOE irradiation on H-14

**Figure S12.** Uprolide O, <sup>1</sup>H-NMR spectrum

**Figure S13.** Uprolide O, <sup>13</sup>C-NMR spectrum

**Figure S14.** Uprolide O, <sup>13</sup>C-NMR-DEPT 135 spectrum

**Figure S15.** Uprolide O, <sup>1</sup>H-<sup>1</sup>H-COSY spectrum

**Figure S16.** Uprolide O, HSQC spectrum

**Figure S17.** Uprolide O, HMBC spectrum

**Figure S18.** Uprolide O, 1D NOE irradiation on H-1

**Figure S19.** Uprolide O, 1D NOE irradiation on H-6/H-17

**Figure S20.** Uprolide O, 1D NOE irradiation on H-7

**Figure S21.** Uprolide O, 1D NOE irradiation on H-11

**Figure S22.** Uprolide O, 1D NOE irradiation on H-14

**Figure S23.** Uprolide O, 1D NOE irradiation on H-17

**Figure S24.** Uprolide P, <sup>1</sup>H-NMR spectrum

**Figure S25.** Uprolide P, <sup>13</sup>C-NMR spectrum

**Figure S26.** Uprolide P, <sup>13</sup>C-NMR DEPT 135 spectrum

**Figure S27.** Uprolide P, <sup>1</sup>H-<sup>1</sup>H-COSY spectrum

**Figure S28.** Uprolide P, HSQC spectrum

**Figure S29.** Uprolide P, HMBC spectrum

**Figure S30.** Uprolide P, 1D NOE irradiation on H-1

**Figure S31.** Uprolide P, 1D NOE irradiation on H-7

**Figure S32.** Uprolide P, 1D NOE irradiation on H-11

**Figure S33.** Uprolide P, 1D NOE irradiation on H-14

**Figure S34.** Uprolide P, 1D NOE irradiation on H-19a

**Figure S35.** Uprolide P, 1D NOE irradiation on H-19b

**Figure S36.** Uprolide P, 1D NOE irradiation on H-20

**Figure S37.** Uprolide N, HRESITOF-MS

**Figure S38.** Uprolide O, ESI-TOF-MS

**Figure S39.** Uprolide P, ESI-TOF-MS

**Figure S40.** Uprolide N IR spectrum

**Figure S41.** Uprolide O IR spectrum

**Figure S42.** Uprolide P IR spectrum


**Figure S43.** Dolabellane, <sup>1</sup>H-NMR spectrum


**Figure S44.** Dolabellane, <sup>13</sup>C-NMR spectrum

**Figure S45.** Dolabellane, LRAPCI-MS


**Figure S46.** Uprolides N, O and P inhibit the production of inflammatory mediators induced by LPS in murine macrophages


**Figure S47:** Compounds N and P do not induced the production of TNF and IL-6

Figure S1. Uprolide N, <sup>1</sup>H-NMR spectrum.

Figure S2. Uprolide N, <sup>13</sup>C-NMR spectrum.



Figure S3. Uprolide N,  $^{13}\text{C}$ -NMR-DEPT 135 spectrum.

Figure S4. Uprolide N,  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum.




Figure S5. Uprolide N, HSQC spectrum.




Figure S6. Uprolide N, HMBC spectrum.




Figure S7. Uprolide N, 1D NOE irradiation on H-1.




Figure S8. Uprolide N, 1D NOE irradiation on H-6.






Figure S9. Uprolide N, 1D NOE irradiation on H-7.




Figure S10. Uprolide N, 1D NOE irradiation on H-11.










Figure S11. Uprolide N, 1D NOE irradiation on H-14.

Figure S12. Uprolide O, <sup>1</sup>H-NMR spectrum.

Figure S13. Uplide O, <sup>13</sup>C-NMR spectrum.

Figure S14. Uprolide O,  $^{13}\text{C}$ -NMR-DEPT 135 spectrum.

Figure S15. Uprolide O,  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum.




Figure S16. Uprolide O, HSQC spectrum.






Figure S17. Uprolide O, HMBC spectrum.




Figure S18. Uprolide O, 1D NOE irradiation on H-1.






Figure S19. Uprolide O, 1D NOE irradiation on H-6/H-17.




Figure S20. Uprolide O, 1D NOE irradiation on H-7.




Figure S21. Uprolide O, 1d NOE irradiation on H-11.




Figure S22. Uprolide O, 1D NOE irradiation on H-14.







Figure S23. Uprolide O, 1D NOE irradiation on H-17


Figure S24. Uprolide P, <sup>1</sup>H-NMR spectrum.

Figure S25. Uprolide P,  $^{13}\text{C}$ -NMR spectrum.



Figure S26. Uprolide P,  $^{13}\text{C}$ -NMR-DEPT 135 spectrum.



Figure S27. Uprolide P,  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum.




Figure S28. Uprolide P, HSQC spectrum.




Figure S29. Uprolide P, HMBC spectrum.




Figure S30. Uprolide P, 1D NOE irradiation on H-1.




Figure S31. Uprolide P, 1D NOE irradiation on H-7.




Figure S32. Uprolide P, 1D NOE irradiation on H-11.






Figure S33. Uprolide P, 1D NOE irradiation on H-14.




Figure S34. Uprolide P, 1D NOE irradiation on H-19a.






Figure S35. Uprolide P, 1D NOE irradiation on H-19b.




Figure S36. Uprolide P, 1D NOE irradiation on H-20.


**Analysis Info**

Analysis Name    \\Qt20251\d\Data\Experimentos\DTorres\20160607\Eunicea-E\_39-61-ACN\_Agil\_C18\_P1-A-2\_01\_3487.d  
 Method            tune\_wide\_lc.m  
 Sample Name      Eunicea-E\_39-61-ACN\_Agil\_C18  
 Comment

Acquisition Date  6/8/2016 12:57:42 PM  
 Operator          BDAL@DE  
 Instrument        micrOTOF-Q III 228888.20451

**Acquisition Parameter**

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	2.0 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	10.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	680.0 Vpp	Set Divert Valve	Waste



Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdb	e <sup>-</sup> Conf	N-Rule
347.1871	1	C <sub>20</sub> H <sub>27</sub> O <sub>5</sub>	347.1853	-5.0	74.9	1	100.00	7.5	even	ok

Figure S37. Uprolide N, HRESITOF-MS.

## Compound Spectrum SmartFormula Report

### Analysis Info

Analysis Name	G:\microTOF-QIII Data (ESI & APCI)\Users\DTorres\uprolido-O_20150421_res.d
Method	tune_wide-low_dir_ms2_gard2014.m
Sample Name	uprolido-O_20150421_res
Comment	Concentration: 50 ug/mL Prepared on: 20150421

Acquisition Date 4/21/2015 12:07:50 PM

Operator BDAL@DE

Instrument microTOF-Q III 228888.10451


Spiked with Reserpine standard 0.5 ug/mL for lock mass calibration  
Dissolved in 100% Methanol

### Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	265.0 Vpp	Set Divert Valve	Waste

#	RT [s]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [s]
n.a.	5.2	n.a.	Single spectrum	n.a.	n.a.	n.a.	385.1615	n.a.

### +MS, 5.2s #12



Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdB	e <sup>-</sup> Conf	N-Rule
385.1615	1	C20H26NaO6	385.1622	1.7	55.0	1	100.00	7.5	even	ok

Figure S38. Uprolide O, HRESITOF-MS.

## Compound Spectrum SmartFormula Report

### Analysis Info

Analysis Name	\\Qt20251\l\Data\Experimentos\DTorres\20160531\Uprolido-p+reserpine.d
Method	tune_wide.m
Sample Name	Uprolido-p
Comment	Concentration: 100 ug/mL Prepared on: 20160531

Acquisition Date 5/31/2016 3:30:36 PM

Operator BDAL@DE

Instrument microTOF-Q III 228888.20451


Spiked with reserpine 0.5 ug/mL  
Dissolved in 100% Methanol

### Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	550.0 Vpp	Set Divert Valve	Source

#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
n.a.	0.2	n.a.	Single spectrum	n.a.	n.a.	n.a.	369.1665	n.a.

### +MS, 0.2min #11



Meas. m/z	#	Ion Formula	m/z	err [ppm]	mSigma	# Sigma	Score	rdB	e <sup>-</sup> Conf	N-Rule
385.1620	1	C20H26NaO6	385.1622	0.4	422.9	1	100.00	7.5	even	ok

Figure S39. Uprolido P, HRESITOF-MS spectrum.




Figure S40. Uprolide N IR spectrum.






Figure S41. Uprolide O IR spectrum.






Figure S42. Uprolide P, IR spectrum.



Figure S43. Dolabellane, <sup>1</sup>H-NMR spectrum.

Figure S44. Dolabellane,  $^{13}\text{C}$ -NMR spectrum.

File: masa exacta MD2-121-04 HPLC\_6Date Run: 09-08-2010 (Time Run: 16:27:29)

Sample: fraccion coral Eunicea masa exacta

Instrument: JEOL LCmate

Inlet: My Inlet

Ionization mode: APCI+

Scan: 149

R.T.: 3.72

Base: m/z 303; 23.8%FS TIC: 829328

#Ions: 311






Figure S45. Dolabellane, LRAPCI-MS.



**Figure S46.** Uprolides N, O and P inhibit the production of inflammatory mediators induced by LPS in murine macrophages. IC<sub>50</sub> sigmoidal curves calculated by the statistical software package GraphPad Prism 5 from a representative experiments of two Graphs represent the sigmoidal curves for the IC<sub>50</sub> calculation of TNF (left column) and IL-6 (right column) induced by LPS in the presence of the uprolides N, O or P. Results represent means ± S.D. from stimuli performed in duplicates.



**Figure S47.** Compound N and P do not induced the production of TNF and IL-6. Macrophages from C57B1/6 mice were treated with 7  $\mu$ M of compounds 1 or 3 (uprolides N or P) 1 h before stimulation with 100  $\mu$ g/mL of LPS. The supernatants were harvested after 16 h, and cytokine concentrations were determined by ELISA. The cell viability was assessed using MTT assay after collecting the supernatants. Results are represented as Mean  $\pm$  SD from stimuli performed in duplicate.